Error message

There was an error processing your request.

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

Jun 02, 2024 23:01 ET
AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Experiences
Today, during Computex 2024, AMD (NASDAQ: AMD) announced a groundbreaking series of next-generation architecture and products aimed at ushering in a new era of AI experiences. AMD is introducing new AMD Ryzen™ AI 300 Series processors with the...
Jun 02, 2024 23:00 ET
AMD Accelerates Pace of Data Center AI Innovation and Leadership with Expanded AMD Instinct GPU Roadmap
At Computex 2024, AMD (NASDAQ: AMD) showcased the growing momentum of the AMD Instinct™ accelerator family during the opening keynote by Chair and CEO Dr. Lisa Su. AMD unveiled a multiyear, expanded AMD Instinct accelerator roadmap which will bring...
Jun 02, 2024 22:59 ET
AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024
Today at the Computex 2024 opening keynote, AMD (NASDAQ: AMD) detailed new leadership CPU, NPU and GPU architectures powering end-to-end AI infrastructure from the data center to PCs. AMD unveiled an expanded AMD Instinct™ accelerator roadmap,...
Jun 02, 2024 22:13 ET
Flash News: OKX Launches 100% Fee Rebate Campaign
OKX, a leading crypto exchange and Web3 technology company, has issued updates for June 3, 2024. OKX Launches '100% Fee Rebate' Campaign OKX today announced a '100% Fee Rebate' Campaign, which allows new customers to enjoy 100% trading fee...
Jun 02, 2024 20:38 ET
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that it has entered into a clinical trial...
Jun 02, 2024 20:23 ET
Mesoblast Corporate Presentation at Investor Conference
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License...
Jun 02, 2024 20:00 ET
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that results from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in...
Jun 02, 2024 19:00 ET
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon...
Jun 02, 2024 18:43 ET
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational...
Jun 02, 2024 17:07 ET
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
Allergic diseases cost between 1,823€ and 6,656€ per patient per year if we only consider the direct costs derived from healthcare, according to a study of the data collected through the European HEAD registry promoted by the EAACI, which is...
Jun 02, 2024 12:30 ET
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145...
Jun 02, 2024 11:31 ET
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
In an era where healthcare innovation is paramount, KFSHRC Jeddah has made headway in the treatment of severe Xanthoma through the deployment of a modified plasma exchange protocol. This milestone underscores KFSHRC's position as a trailblazer in...
Jun 02, 2024 11:27 ET
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
OKX, a leading crypto exchange and Web3 technology company, has issued updates for June 2, 2024. OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet OKX is pleased to announce that it now supports Wormhole Protocol's W Token on...
Jun 02, 2024 10:55 ET
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to date...
Jun 02, 2024 10:00 ET
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster...
Jun 02, 2024 10:00 ET
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Ther
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases,...
Jun 02, 2024 10:00 ET
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple
Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared two scientific poster presentations from the 2024 American Society of...
Jun 02, 2024 09:51 ET
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, both dates inclusive (the “Class Period”), have until July 22, 2024 to seek appointment...
Jun 02, 2024 09:01 ET
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by...
Jun 02, 2024 08:56 ET
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
COMPUTEX -- To address the increasing need for real-time AI computing at the industrial edge, NVIDIA today announced the general software availability of NVIDIA AI Enterprise-IGX with NVIDIA Holoscan on the NVIDIA IGX™ platform. Together, they...